Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.56 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.56 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.56 |
| ▸ | RORC | P51449 | 8/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154068 | 0.88 | KCNQ3 (0.54) | KCNQ3KCNQ2KCNQ4KCNQ5RORC | |
| SCHEMBL6086484 | 0.88 | KCNQ3 (0.56) | KCNQ3KCNQ2KCNQ4KCNQ5RORC | |
| SCHEMBL28046571 | 0.88 | HDAC8 (0.58) | KCNQ3KCNQ2KCNQ4KCNQ5MAOB | |
| SCHEMBL28046564 | 0.86 | KCNQ3 (0.55) | KCNQ3KCNQ2KCNQ4KCNQ5RORC | |
| SCHEMBL6085966 | 0.86 | KCNQ3 (0.55) | KCNQ3KCNQ2KCNQ4KCNQ5RORC | |
| SCHEMBL28046562 | 0.85 | HDAC8 (0.64) | KCNQ3KCNQ2KCNQ4KCNQ5MAOB | |
| SCHEMBL15601501 | 0.85 | KCNQ3 (0.52) | KCNQ3KCNQ2KCNQ4KCNQ5RORC | |
| SCHEMBL15601447 | 0.84 | KCNQ3 (0.53) | KCNQ3KCNQ2KCNQ4KCNQ5MAOB | |
| SCHEMBL15601462 | 0.84 | EPHX2 (0.64) | KCNQ3KCNQ2KCNQ4KCNQ5RORC | |
| SCHEMBL15601409 | 0.84 | KCNQ3 (0.65) | KCNQ3KCNQ2KCNQ4KCNQ5RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321750-B2 | ROR modulators and their uses | INNOV17 LLC (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321750-B2 | ROR modulators and their uses | INNOV17 LLC (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150284366-A1 | ROR MODULATORS AND THEIR USES | INNOV17 LLC | 2015-10-08 | — | — | US | disclosed |
| US-20150284366-A1 | ROR MODULATORS AND THEIR USES | INNOV17 LLC | 2015-10-08 | — | — | US | disclosed |
| WO-2013159095-A1 | ROR MODULATORS AND THEIR USES | GAWECO ANDERSON (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284366-A1 | ROR MODULATORS AND THEIR USES | RORA, RORB, RORC | KCNQ3 3019/4885KCNQ2 3011/4885KCNQ4 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.